Theravance Biopharma(TBPH) - 2025 Q1 - Quarterly Results

Exhibit 99.1 Theravance Biopharma, Inc. Reports First Quarter 2025 Financial Results and Provides Corporate Update DUBLIN, IRELAND – MAY 8, 2025 – Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today reported financial and operational results for the first quarter of 2025. "As we begin the year, we remain focused on delivering against our operational priorities for YUPELRI and ampreloxetine," said Rick E Winningham, CEO of Theravance Biopharma. "Our commercial partnershi ...